Oculus Innovative Sciences Inc (Petaluma, Calif) recently received 510(k) clearance from the US Food and Drug Administration to market its Microcyn® Skin and Wound Gel as both a prescription and over-the-counter formulation. The Rx product is intended for management of exuding wounds such as leg ulcers, pressure ulcers, diabetic ulcers, and for the management of mechanically or surgically debrided wounds—under the supervision of a healthcare professional. This is the first hydrogel product based upon the Microcyn Technology platform and is reimbursable by both Medicare and Medicaid.

Visit www.oculusis.com for more information.